FDA Says GlaxoSmithKline’s Advair 500/50 “Not Approvable” For COPD
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency questions efficacy of COPD treatment over lower strength; GSK tells “The Pink Sheet” DAILY that head-to-head trials were not conducted.
You may also be interested in...
FDA Grants GSK's Advair Broader Use
Top-selling asthma drug cleared for COPD flare-ups.
FDA Grants GSK's Advair Broader Use
Top-selling asthma drug cleared for COPD flare-ups.
Avandia Market Share Stabilizing, GSK CEO Garnier Says
In his last earnings presentation, Garnier says it is unclear whether the type 2 diabetes drug will become a growth driver again.